NLRP3 and colitis: Of interest, our results are consistent with the findings of a recent study, showing that the direct and selective blockade of inflammasome with MCC950, the most specific and well characterized NLRP3 inhibitor available so far, attenuated colonic inflammation in mice with spontaneous colitis, likely through the inhibition of both canonical and non-canonical NLRP3 activation (Perera et al., 2018).